Financials and Corporate

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will co-host with the Icahn School of Medicine at Mount Sinai a scientific symposium entitled “ Next Generation...

Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024 NK-Cell engager SAR443579/IPH6101 1 first-in-human study advanced to Phase 2 and initiation of...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that Arvind Sood, EVP, President of US Operations, is to participate in the upcoming investor...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced members of its executive team are scheduled to participate in the upcoming conference, detailed...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced members of its executive team are scheduled to participate in the upcoming conferences, detailed...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 23...

First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024 Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101...